LEPU ScienTech Medical Technology (Shanghai) Co., Ltd. Share Price

Equities

2291

CNE1000057M5

Medical Equipment, Supplies & Distribution

Market Closed - Hong Kong S.E. 09:08:20 26/04/2024 BST 5-day change 1st Jan Change
22.25 HKD +1.14% Intraday chart for LEPU ScienTech Medical Technology (Shanghai) Co., Ltd. -0.67% -18.20%

Financials

Sales 2022 248M 34.18M 268M 2.74B Sales 2023 326M 44.98M 352M 3.6B Capitalization 8.57B 1.18B 9.26B 94.74B
Net income 2022 -19M -2.62M -20.53M -210M Net income 2023 152M 20.98M 164M 1.68B EV / Sales 2022 30.6 x
Net cash position 2022 1.2B 166M 1.3B 13.25B Net cash position 2023 1.26B 174M 1.37B 13.97B EV / Sales 2023 22.4 x
P/E ratio 2022
-418 x
P/E ratio 2023
56.6 x
Employees 219
Yield 2022 *
-
Yield 2023
2.31%
Free-Float 19.25%
More Fundamentals * Assessed data
Dynamic Chart
1 day+1.14%
1 week-0.67%
Current month-15.08%
1 month-17.29%
3 months-15.24%
6 months-19.96%
Current year-18.20%
More quotes
1 week
21.55
Extreme 21.55
23.20
1 month
21.55
Extreme 21.55
28.15
Current year
21.55
Extreme 21.55
29.80
1 year
21.55
Extreme 21.55
35.50
3 years
21.55
Extreme 21.55
43.00
5 years
21.55
Extreme 21.55
43.00
10 years
21.55
Extreme 21.55
43.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 52 28/01/21
Director of Finance/CFO 47 27/05/21
Chief Operating Officer 43 27/05/21
Members of the board TitleAgeSince
Director/Board Member 50 01/09/21
Director/Board Member 56 08/06/21
Director/Board Member 62 28/01/21
More insiders
Date Price Change Volume
26/04/24 22.25 +1.14% 617,000
25/04/24 22 -1.12% 92,000
24/04/24 22.25 -1.77% 91,000
23/04/24 22.65 -0.88% 88,000
22/04/24 22.85 +2.01% 106,000

Delayed Quote Hong Kong S.E., April 26, 2024 at 09:08 am

More quotes
Lepu Scientech Medical Technology Shanghai Co Ltd is a China-based investment holding company mainly engaged in the research and development, manufacturing and commercialization of interventional medical devices for structural heart disease. The Company operates primarily through two segments. The Occluder Business segment is mainly engaged in the research and development and sales of a series of interventional treatment series occluders for defective congenital heart disease. The Heart Valve Business segment is mainly engaged in the research and development of heart valve medical devices. The Company operates primarily in the domestic market.
Calendar
More about the company